Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Bitcoin Whales Continue Accumulating in April, Large Wallet Count Hits Four-Month High

Bitcoin Whales Continue Accumulating in April, Large Wallet Count Hits Four-Month High

ChaincatcherChaincatcher2025/04/21 05:35
Show original

According to ChainCatcher, as reported by Cointelegraph, despite Bitcoin's price dip in early April, whales have been actively accumulating.

Data from Glassnode shows that since early March, the number of wallets holding more than 1,000 Bitcoins has increased by over 60, reaching 2,107 as of April 15, the highest in four months. This data has returned to the levels seen during the market rally in November and December last year.

Meanwhile, Bitcoin's price has broken through the sideways consolidation that began in early March, reaching $87,400 on April 21 for the first time since March 28. Analysts believe that Bitcoin's breakout from a multi-month descending wedge chart pattern could signal a bullish reversal, with prices potentially returning to six figures in May.

 
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Intel Confirms Advancement of Musk's "Terafab" Chip Plan Amid Stock Price Pressure

Intel CEO Pat Gelsinger stated that the company will continue to participate in Elon Musk's Terafab project. Previously, Musk revealed ongoing discussions with TSMC about potential collaboration, which raised market concerns over Intel's position in the project. As a result, Intel's stock price once dropped by 3.9%.

华尔街见闻•2026/10/07 10:09

BUZZ-Caribou shares plunge as company explores sale and cancels cancer project

October 7 - ** Caribou Biosciences (CRBU.O) shares fell 35.9% in pre-market trading to $0.72 ** Caribou Biosciences announced late Tuesday that it is exploring strategic options, including a potential sale, merger, or other transactions, to maximize shareholder value ** Caribou said it plans to halt development of its allogeneic CAR-T cell therapy programs, including vispa-cel for non-Hodgkin lymphoma and CB-011 for multiple myeloma ** Caribou also stated it will lay off employees and cut costs, with most layoffs expected to be completed by Q4 2026 ** As of June 30, the company held $113.8 millions in cash, cash equivalents, and marketable securities ** As of the previous trading day's close, the company's share price had dropped about 28% year-to-date (Note: For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Since automated translations may be inaccurate or lack necessary context, Reuters does not guarantee the accuracy of automated translation texts and provides them only for reader convenience. Reuters assumes no responsibility for any damages or losses resulting from the use of automated translation features.)

路透社•2026/10/07 09:39